Peripheral blood inflammatory biomarkers neutrophil/ lymphocyte ratio, platelet/lymphocyte ratio and systemic immune-inflammation index/albumin ratio predict prognosis and efficacy in non-small cell lung cancer patients receiving immunotherapy and opioids

Abstract

Objective: The study aimed to assess the value of pretreatment peripheral blood neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR) and systemic immune-inflammation index/albumin ratio (SII/ALB) for predicting immunotherapy prognosis and efficacy in Non-small cell lung carcinoma (NSCLC) treated with Immune checkpoint inhibitors (ICIs) and opioids. Methods: A total of 78 NSCLC patients received ICIs and opioids were retrospectively collected. The optimal cut-off values were determined by receiver operating characteristic curves. The univariate and multivariate analysis investigated the effects of NLR, PLR, and SII/ALB on patients prognosis. Results: NLR and PLR had predictive value of efficacy. SII/ALB > 17.79 was an independent risk factor for worse outcomes. Conclusion: PLR and SII/ALB have predictive value of efficacy, but NLR was not. SII/ALB > 17.79 suggests a poor prognosis following immunotherapy in NSCLC patients receiving ICIs and opioids.